Medidata Solutions
announced that Keio Center for Clinical Research (CCR), one of Japan’s two centers of excellence promoting global clinical research, has chosen to standardize on
Medidata Rave
® as its electronic data capture (EDC) and clinical data management (CDM) solution.
Keio CCR was founded in 2006 as an academic research organization within Keio University School of Medicine under the auspices of the Ministry of Health, Labor and Welfare (MHLW) to assume a role in the national improvement of clinical trial infrastructure. Designated by the MHLW in 2009 as one of two centers of excellence to promote global clinical research, Keio CCR plans and supports investigator-initiated, non-NDA clinical trials and observational clinical research, as well as industry-sponsored translational research, registration trials and post-marketing studies.
“Medidata Rave will be key to supporting our strategy of facilitating high-quality clinical research while looking to deliver optimum treatments and improve patient welfare,” said Keio University Center for Clinical Research Professor Yuji Sato MD., PhD.
Keio CCR is upgrading its EDC solution in order to continue to expand, accelerate and improve the quality of its multinational and multicenter clinical studies. Medidata Rave’s investigator-friendly system, which was originally developed for academic clinical trials, will enable Keio CCR to continue to grow its clinical research capabilities.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.